John C. Martin, PhD, joined Gilead Sciences in 1990 and served as Chief Executive Officer from 1996 to 2016, during which time Gilead became the leading company in antiviral drug development and commercialization.
Prior to joining Gilead, he held several leadership positions at Bristol-Myers Squib and Syntex Corporation. He invented ganciclovir in 1982 and contributed to the commercialization of a number of antiviral drugs active against HIV, cytomegalovirus, influenza, and hepatitis B and C. Dr. Martin previously served as President of the International Society of Antiviral Research and Chairman of both BayBio and California Healthcare Institute. He served on the National Institute of Allergy & Infectious Diseases Council and the Board of Trustees of Golden Gate University, University of Chicago, and University of Southern California. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administration’s Advisory Council on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He is currently a trustee for The Scripps Research Institute.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago, an MBA from Golden Gate University, and a BS in chemical engineering from Purdue University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering.